DE69030956T2 - Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix - Google Patents

Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix

Info

Publication number
DE69030956T2
DE69030956T2 DE69030956T DE69030956T DE69030956T2 DE 69030956 T2 DE69030956 T2 DE 69030956T2 DE 69030956 T DE69030956 T DE 69030956T DE 69030956 T DE69030956 T DE 69030956T DE 69030956 T2 DE69030956 T2 DE 69030956T2
Authority
DE
Germany
Prior art keywords
pathologies
accumulation
growth factor
extracellular matrix
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69030956T
Other languages
English (en)
Other versions
DE69030956D1 (de
Inventor
Wayne Border
Erkki Ruoslahti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of DE69030956D1 publication Critical patent/DE69030956D1/de
Application granted granted Critical
Publication of DE69030956T2 publication Critical patent/DE69030956T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
DE69030956T 1989-09-29 1990-09-27 Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix Expired - Lifetime DE69030956T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41508189A 1989-09-29 1989-09-29
US41665689A 1989-10-03 1989-10-03
PCT/US1990/005566 WO1991004748A1 (en) 1989-09-29 1990-09-27 INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX

Publications (2)

Publication Number Publication Date
DE69030956D1 DE69030956D1 (de) 1997-07-24
DE69030956T2 true DE69030956T2 (de) 1998-01-15

Family

ID=27022856

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69030956T Expired - Lifetime DE69030956T2 (de) 1989-09-29 1990-09-27 Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix

Country Status (10)

Country Link
EP (2) EP0775742A3 (de)
JP (1) JPH0780780B2 (de)
AT (1) ATE154514T1 (de)
AU (1) AU654938B2 (de)
CA (1) CA2065860C (de)
DE (1) DE69030956T2 (de)
DK (1) DK0494264T3 (de)
FI (1) FI921353A (de)
NO (1) NO921119D0 (de)
WO (1) WO1991004748A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
DE69228700T2 (de) * 1991-12-04 1999-09-09 Jolla Cancer Res Found Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5395825A (en) * 1993-03-10 1995-03-07 Yale University Fertility regulation with transforming growth factor β
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
EP0754058B1 (de) * 1994-03-29 1999-11-03 The Victoria University Of Manchester Wundheilung
EP1741780A3 (de) * 1995-06-02 2007-03-28 Gilead Sciences, Inc. Ologonukleotidliganden mit höher Affinität für Wachstumsfaktoren
GB2304045A (en) † 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU771635B2 (en) 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2400628A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
JP4566605B2 (ja) * 2004-04-02 2010-10-20 有限会社開発顧問室 短鎖ペプチドを有効成分とするコラーゲン合成阻害剤およびその製造方法
DK1842557T3 (da) 2004-12-22 2013-12-02 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til inhibition af fibrose
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
EP1948675B1 (de) 2005-10-25 2014-07-30 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
ES2647472T3 (es) 2006-10-03 2017-12-21 Genzyme Corporation Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
WO2012090997A1 (ja) 2010-12-27 2012-07-05 京都府公立大学法人 ｉＰＳ細胞とその製造法
SG10201902706VA (en) 2011-06-03 2019-04-29 Xoma Technology Ltd Antibodies specific for tgf-beta
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
US11382904B2 (en) 2013-10-31 2022-07-12 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US9976142B2 (en) 2014-04-02 2018-05-22 Nitto Denko Corporation Targeting molecule and a use thereof
JP6480467B2 (ja) 2014-04-07 2019-03-13 日東電工株式会社 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ
US10092891B2 (en) 2014-04-25 2018-10-09 University Of Florida Research Foundation, Incorporated Controlling the activity of growth factors, particularly TGF-β, in vivo
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2018064515A1 (en) * 2016-09-30 2018-04-05 Academia Sinica Microrna let-7 and transforming growth factor beta receptor iii axis as target for cardiac injuries
JP2022543227A (ja) * 2019-07-31 2022-10-11 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー 線維性マトリックス蓄積の阻害剤としてのペプチド
EP3771464A1 (de) 2019-07-31 2021-02-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptide als inhibitoren der fibrotischen matrixakkumulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors

Also Published As

Publication number Publication date
CA2065860C (en) 2001-03-27
DE69030956D1 (de) 1997-07-24
NO921119L (no) 1992-03-20
NO921119D0 (no) 1992-03-20
JPH0780780B2 (ja) 1995-08-30
CA2065860A1 (en) 1991-03-30
EP0494264A1 (de) 1992-07-15
WO1991004748A1 (en) 1991-04-18
AU6612590A (en) 1991-04-28
EP0775742A3 (de) 1998-01-14
DK0494264T3 (da) 1998-01-26
FI921353A0 (fi) 1992-03-27
EP0494264B1 (de) 1997-06-18
AU654938B2 (en) 1994-12-01
FI921353A (fi) 1992-03-27
ATE154514T1 (de) 1997-07-15
JPH05503076A (ja) 1993-05-27
EP0775742A2 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
ATE154514T1 (de) Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix
ES2114065T3 (es) Metodo para el diagnostico y control de la sepsis.
DE3853236D1 (de) Apparat und Methode zur Überwachung des Türantriebes und der Fahrt eines Aufzuges.
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
DE69723429D1 (de) Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
DE69432395D1 (de) Verfahren und Vorrichtung zur tomographischen Abbildung des Augenhintergrundes mittels optischer Kohärenz
DE3778677D1 (de) Einrichtung und verfahren zur bildsubstrahierung mit verminderung des bewegungsartefakts.
ES2062241T3 (es) Metodo de purificacion de la albumina serica humana.
DE69626517D1 (de) Methode zur behandlung der corticosteroid-induzierten orteopenie
DK450487D0 (da) Apparat til medicinsk behandling med udladninger fra bipolare elektroder
ES510923A0 (es) Procedimiento y su correspondiente aparato para el adormeci-miento de animales de matanza.
EP0515434A4 (en) Method for treating intestinal diseases
NO922573L (no) Fremgangsmaate for aa paavise ben- og andre bindevevsforstyrrelser hos mennesker og dyr
DE69735883D1 (de) Methode zur behandlung von muskelkrankheiten
DE69133074D1 (de) Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten
NO882373D0 (no) Fremgangsmaate for silicopyrohydrolysebehandling av brukte hall-heroult-elektrolysetanker.
DK0590309T3 (da) Knoglevævsbeslægtet protein, fremgangsmåde til dets fremstilling samt lægemiddel med indhold deraf
EP0158987A3 (en) Use of gonadoliberin and its antagonists in the treatment of menopause
Galey et al. Spontaneous alternation disturbance after lesions of the ventral mesencephalic tegmentum in the rat
SU639532A1 (ru) Способ полиостеосинтеза и устройство дл его осуществлени
IT8944004A0 (it) Procedimento per l'impianto di trattamento totale dei fumi provenienti da processi di combustione
BE869147A (fr) Procede pour eliminer l'attaque des cathodes au niveau de la solution pendant l'electrolyse
Schellenberg et al. The method of nasopharyngeal EEG recording from structures near the hippocampus in schizophrenic patients and normals
DE3764322D1 (de) Vorrichtung zur abstuetzung des rahmens bzw. aufbau eines fahrzeuges.
ATE55581T1 (de) Vorrichtung zur abstuetzung des rahmens bzw. aufbau eines fahrzeuges.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition